Author:
Karamian Farivash,Sadeghi Ramin,Aghaee Atena,Askari Emran,Roustaei Hessamoddin
Abstract
Abstract
The cancer specificity of fibroblast activation protein inhibitor (FAPI) uptake remains understudied topic, and several cases of false-positive FAPI PET/CT findings have been reported. We present 2 patients of differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy syndrome who underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT for evaluation of any possible sites for metastatic disease. Although no focus of metastatic disease was found in these patients, remarkable findings were noticed instead. Nonmalignant FAPI uptake was evident in the gallbladder, uterus, and degenerative changes, whereas these uptake were discordant or partially concordant with those in FDG’s, also CT images showed no underlying abnormality.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference13 articles.
1. A tumor-imaging method targeting cancer-associated fibroblasts;J Nucl Med,2018
2. FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology?;J Nucl Med,2021
3. Could fibroblast activation protein (FAP)-specific radioligands be considered as pan-tumor agents?;Contrast Media Mol Imaging,2022
4. FAPI-04 uptake in healthy tissues of cancer patients in 68Ga-FAPI-04 PET/CT imaging;Contrast Media Mol Imaging,2021
5. FAPI-avid nonmalignant PET/CT findings: an expedited systematic review;Semin Nucl Med,2023